Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Granisetron Transdermal Patch System for Prevention of Chemotherapy-induced Delayed Nausea and Vomiting by CapeOX：A Single-Arm, Open-Label, Phase II Study.

NCT05325190 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.

NCT NCT05325190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05325190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Granisetron Transdermal Patch System for Prevention of Chemotherapy-induced Delayed Nausea and Vomiting by CapeOX：A Single-Arm, Open-Label, Phase II Study.
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
October 10, 2021
Completion date
June 1, 2023
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting